ACOG News & Events

Alpha Cognition announced changes to its Board of Directors. Robert Wills has been elected Chairman of the Board, succeeding Len Mertz, who has retired from the Board after years of dedicated service and leadership. Wills has served on Alpha Cognition's Board of Directors since 2025, and currently serves as Chair of the Governance and Nominating Committee and as a member of the Audit Committee.

Alpha Cognition announced the enrollment of the first patient in RESOLVE, a Phase 4 post-marketing clinical study designed to further evaluate the tolerability profile and treatment experience associated with ZUNVEYL in routine clinical practice. The RESOLVE study is expected to enroll approximately 150 patients across multiple clinical sites and will monitor adverse events, treatment persistence, and discontinuation rates throughout the study. Data generated from RESOLVE is expected to complement findings from previous clinical studies and contribute to the growing body of evidence supporting the use of ZUNVEYL in clinical practice.